Literature DB >> 1917047

Cutaneous manifestations of Lyme borreliosis.

E Aberer1, H Klade.   

Abstract

The dermatological symptoms of Lyme borreliosis present with a typical clinical pattern and characteristic time of appearance. In contrast to other manifestations of Lyme borreliosis they are easily recognizable in most of the cases. In the first stage, erythema migrans arises at the tick bite site. With this symptom the diagnosis of Lyme borreliosis can be established. During all manifestations of Lyme borreliosis the history of erythema migrans is an important parameter to verify the diagnosis. In the early stage of disease a lymphocytic proliferation can appear at the tick bite site, at the ear lobe, or at the mamilla. Borrelia lymphocytoma can be diagnosed when antibodies against Borrelia burgdorferi are positive. Years after infection, acrodermatitis chronica atrophicans arises at distal body sites causing livid swelling and gradually skin atrophy. Skin lesions can be accompanied by neuropathies, mostly of the lower legs, which in contrast to the skin lesions, do not respond well to antibiotic therapy. There is evidence that some cases of Shulman syndrome, morphea and lichen sclerosus et atrophicus might be related to a borrelia infection as indicated by cultivation of B. burgdorferi from skin biopsies of morphea and response to antibiotic treatment in some cases. The classical dermatological symptoms of Lyme borreliosis, erythema migrans, borrelia lymphocytoma and acrodermatitis chronica atrophicans respond to oral antibiotic treatment. In acrodermatitis chronica atrophicans parenteral antibiotic therapy is sometimes necessary.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1917047     DOI: 10.1007/bf01644968

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

1.  Treating erythema chronicum migrans of Lyme disease.

Authors:  B W Berger
Journal:  J Am Acad Dermatol       Date:  1986-09       Impact factor: 11.527

2.  Evidence for spirochetal origin of Sudeck's atrophy (algodystrophy, reflex sympathetic dystrophy).

Authors:  R A Neumann; E Aberer; G Stanek
Journal:  Arch Orthop Trauma Surg       Date:  1989       Impact factor: 3.067

3.  Histological evidence for spirochetal origin of morphea and lichen sclerosus et atrophicans.

Authors:  E Aberer; G Stanek
Journal:  Am J Dermatopathol       Date:  1987-10       Impact factor: 1.533

Review 4.  The many faces and phases of borreliosis II.

Authors:  D C Abele; K H Anders
Journal:  J Am Acad Dermatol       Date:  1990-09       Impact factor: 11.527

Review 5.  Early and late cutaneous manifestations in Ixodes-borne borreliosis (erythema migrans borreliosis, Lyme borreliosis).

Authors:  E Asbrink; A Hovmark
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

6.  A clinical, histological, and immunohistochemical comparison of acrodermatitis chronica atrophicans and morphea.

Authors:  E Aberer; H Klade; G Hobisch
Journal:  Am J Dermatopathol       Date:  1991-08       Impact factor: 1.533

Review 7.  Erythema chronicum migrans Afzelius and acrodermatitis chronica atrophicans. Early and late manifestations of Ixodes ricinus-borne Borrelia spirochetes.

Authors:  E Asbrink
Journal:  Acta Derm Venereol Suppl (Stockh)       Date:  1985

8.  Borrelia burgdorferi and different types of morphea.

Authors:  E Aberer; H Klade; G Stanek; W Gebhart
Journal:  Dermatologica       Date:  1991

9.  Ear punch biopsy method for detection and isolation of Borrelia burgdorferi from rodents.

Authors:  R J Sinsky; J Piesman
Journal:  J Clin Microbiol       Date:  1989-08       Impact factor: 5.948

10.  The spirochetal etiology of lymphadenosis benigna cutis solitaria.

Authors:  A Hovmark; E Asbrink; I Olsson
Journal:  Acta Derm Venereol       Date:  1986       Impact factor: 4.437

  10 in total
  1 in total

Review 1.  Thyroid Autoimmunity and Lichen.

Authors:  Fabrizio Guarneri; Roberta Giuffrida; Flavia Di Bari; Serafinella Patrizia Cannavò; Salvatore Benvenga
Journal:  Front Endocrinol (Lausanne)       Date:  2017-06-27       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.